Aclaris Therapeutics, Inc. (ACRS) |
|
16.37 -0.1 (-0.61%)
|
08-19 01:39 |
|
Open: |
16.49 |
Pre. Close: |
16.47 |
|
High:
|
16.545 |
Low:
|
16 |
|
Volume:
|
390,934 |
Market Cap:
|
1,091(M) |
|
|
|
|
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
17.1 - 17.18 |
17.18 - 17.25 |
|
Low:
|
16.02 - 16.13 |
16.13 - 16.23 |
|
Close:
|
16.31 - 16.48 |
16.48 - 16.62 |
|
Technical analysis |
as of: 2022-08-18 3:50:32 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 21.71 One year: 25.36 |
| Support: |
Support1: 15.4 Support2: 13.43 |
| Resistance: |
Resistance1: 18.59 Resistance2: 21.71 |
| Pivot: |
16.34  |
| Moving Average: |
MA(5): 16.67  MA(20): 16.12
MA(100): 14.71 MA(250): 14.79 |
| MACD: |
MACD(12,26): 0.4 Signal(9): 0.4 |
| Stochastic oscillator: |
%K(14,3): 61.4 %D(3): 63.4 |
| RSI: |
RSI(14): 52.8 |
| 52-week: |
High: 19.96 Low: 9.26 |
| Average Vol(K): |
3-Month: 375 (K) 10-Days: 399 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ACRS ] has closed below upper band by 47.9%. Bollinger Bands are 37.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Wed, 17 Aug 2022
City of Seattle's Food Equity Fund invests $2.8 million in 22 community-initiated projects - Front Porch - Seattle.gov
Wed, 17 Aug 2022
Joint UK Parliamentary Briefing on Afghanistan - Human Rights Watch
Tue, 16 Aug 2022
Short Interest in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Declines By 9.0% - MarketBeat
Mon, 15 Aug 2022
Pregnant Afghan mum and her two toddlers still stuck in hotel room one year after rescue - The Mirror
Mon, 15 Aug 2022
UK treatment of Afghan refugees ‘continues to be source of shame’ - The Guardian
Wed, 10 Aug 2022
FCDO ‘error’ reveals data on Afghan teacher in hiding from Taliban - The Guardian
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Diagnostics & Research |
| Shares Out. |
0 (M) |
| Shares Float |
67 (M) |
|
% Held by Insiders
|
4.361e+007 (%) |
|
% Held by Institutions
|
3.9 (%) |
|
Shares Short
|
3,570 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-7.316e+007 |
|
EPS Est Next Qtl
|
-1.13 |
|
EPS Est This Year
|
-3.1 |
|
EPS Est Next Year
|
-3.18 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-1 |
|
Return on Assets (ttm)
|
140.3 |
|
Return on Equity (ttm)
|
-23.7 |
|
Qtrly Rev. Growth
|
6.44e+006 |
|
Gross Profit (p.s.)
|
-29.84 |
|
Sales Per Share
|
-90.69 |
|
EBITDA (p.s.)
|
-6.84754e+007 |
|
Qtrly Earnings Growth
|
-1.4 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-61 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
-0.2 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.19 |
|
Price to Cash Flow
|
3.43 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
3.89e+006 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
